Hangzhou Dingle Xinwei Biotechnology Co., Ltd.

Main objectives: 1. To evaluate the safety and tolerability of a single subcutaneous administration of DNV001 injection to subjects. Secondary objectives: 2. To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous administration of DNV001 injection to subjects; 3. To evaluate the pharmacodynamic effect of a single subcutaneous administration of DNV001 injection on serum LDL-C levels; 4. To evaluate the pharmacodynamic effect of a single subcutaneous administration of DNV001 injection on plasma PCSK9 levels; 5. To evaluate the pharmacodynamic effect of a single subcutaneous administration of DNV001 injection on other serum lipid parameters; 6. To evaluate the immunogenicity of a single subcutaneous administration of DNV001 injection to subjects. Exploratory objectives: 7. The effect of a single subcutaneous administration of DNV001 injection on the QT interval of subjects.